Which has preferable earnings & valuation, KYMR or BIIB?

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 229.77 -$311.35M -$3.24 N/A Biogen $9.89B 3.32 $1.29B $5.65 39.32

Does the media prefer KYMR or BIIB?

In the previous week, Biogen had 14 more articles in the media than Kymera Therapeutics. MarketBeat recorded 19 mentions for Biogen and 5 mentions for Kymera Therapeutics. Biogen's average media sentiment score of 0.85 beat Kymera Therapeutics' score of 0.33 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ALNY or KYMR?

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Alnylam Pharmaceuticals and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.33 beat Alnylam Pharmaceuticals' score of 0.21 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KYMR or ROIV?

In the previous week, Roivant Sciences had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Roivant Sciences and 5 mentions for Kymera Therapeutics. Roivant Sciences' average media sentiment score of 0.57 beat Kymera Therapeutics' score of 0.33 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or KYMR?

In the previous week, BioNTech had 15 more articles in the media than Kymera Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 5 mentions for Kymera Therapeutics. BioNTech's average media sentiment score of 0.44 beat Kymera Therapeutics' score of 0.33 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INSM or KYMR more profitable?

Insmed has a net margin of -76.94% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Kymera Therapeutics -285.33% -21.22% -19.21%

Does the media prefer INSM or KYMR?

In the previous week, Insmed had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Insmed and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.33 beat Insmed's score of 0.12 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kymera Therapeutics (KYMR) Competitors

$109.30 +0.95 (+0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$112.79 +3.49 (+3.19%)

As of 07:30 PM Eastern

Compare

KYMR vs. BIIB, ALNY, ROIV, BNTX, and INSM

Should you buy Kymera Therapeutics stock or one of its competitors? Kymera Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), BioNTech (BNTX), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kymera Therapeutics compare to Biogen?

Kymera Therapeutics (NASDAQ:KYMR) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Kymera Therapeutics currently has a consensus price target of $134.46, suggesting a potential upside of 24.10%. Biogen has a consensus price target of $230.14, suggesting a potential upside of 3.60%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kymera Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	229.77	-$311.35M	-$3.24	N/A
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32

Biogen has a net margin of 8.32% compared to Kymera Therapeutics' net margin of -285.33%. Biogen's return on equity of 11.18% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Biogen	8.32%	11.18%	6.88%

Kymera Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biogen had 14 more articles in the media than Kymera Therapeutics. MarketBeat recorded 19 mentions for Biogen and 5 mentions for Kymera Therapeutics. Biogen's average media sentiment score of 0.85 beat Kymera Therapeutics' score of 0.33 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Biogen beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Alnylam Pharmaceuticals had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Alnylam Pharmaceuticals and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.33 beat Alnylam Pharmaceuticals' score of 0.21 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.09	$313.75M	$5.38	41.71
Kymera Therapeutics	$39.21M	229.77	-$311.35M	-$3.24	N/A

Alnylam Pharmaceuticals currently has a consensus price target of $366.90, suggesting a potential upside of 63.50%. Kymera Therapeutics has a consensus price target of $134.46, suggesting a potential upside of 24.10%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Alnylam Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Kymera Therapeutics' net margin of -285.33%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Summary

Alnylam Pharmaceuticals beats Kymera Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Kymera Therapeutics (NASDAQ:KYMR) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Kymera Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $134.46, suggesting a potential upside of 24.10%. Roivant Sciences has a consensus target price of $45.64, suggesting a potential upside of 31.33%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

64.8% of Roivant Sciences shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kymera Therapeutics has a net margin of -285.33% compared to Roivant Sciences' net margin of -3,534.96%. Kymera Therapeutics' return on equity of -21.22% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Roivant Sciences had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Roivant Sciences and 5 mentions for Kymera Therapeutics. Roivant Sciences' average media sentiment score of 0.57 beat Kymera Therapeutics' score of 0.33 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	229.77	-$311.35M	-$3.24	N/A
Roivant Sciences	$8.26M	3,038.82	-$299.77M	-$0.53	N/A

Summary

Kymera Therapeutics beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

BioNTech currently has a consensus target price of $125.69, indicating a potential upside of 31.96%. Kymera Therapeutics has a consensus target price of $134.46, indicating a potential upside of 24.10%. Given BioNTech's higher probable upside, equities analysts plainly believe BioNTech is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, BioNTech had 15 more articles in the media than Kymera Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 5 mentions for Kymera Therapeutics. BioNTech's average media sentiment score of 0.44 beat Kymera Therapeutics' score of 0.33 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Kymera Therapeutics has lower revenue, but higher earnings than BioNTech. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A
Kymera Therapeutics	$39.21M	229.77	-$311.35M	-$3.24	N/A

BioNTech has a net margin of -63.54% compared to Kymera Therapeutics' net margin of -285.33%. BioNTech's return on equity of -6.86% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioNTech beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Insmed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Insmed presently has a consensus target price of $200.57, indicating a potential upside of 97.14%. Kymera Therapeutics has a consensus target price of $134.46, indicating a potential upside of 24.10%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Insmed has a net margin of -76.94% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Kymera Therapeutics has lower revenue, but higher earnings than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.64	-$1.28B	-$4.11	N/A
Kymera Therapeutics	$39.21M	229.77	-$311.35M	-$3.24	N/A

In the previous week, Insmed had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Insmed and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.33 beat Insmed's score of 0.12 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insmed and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.01B	$3.83B	$7.14B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	N/A	13.96	275.15	25.94
Price / Sales	231.79	1,177.92	566.78	84.28
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	5.63	16.11	10.80	6.27
Net Income	-$311.35M	-$22.69M	$3.50B	$382.13M
7 Day Performance	-0.74%	-3.47%	-2.02%	-1.35%
1 Month Performance	-6.16%	-12.68%	-7.53%	-5.60%
1 Year Performance	94.17%	9.60%	3.32%	-1.54%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	2.0718 of 5 stars	$109.30 +0.9%	$134.68 +23.2%	+90.4%	$9.01B	$39.21M	N/A	273	Analyst Forecast
BIIB Biogen	3.3818 of 5 stars	$223.36 -0.1%	$230.14 +3.0%	+45.9%	$33.04B	$9.89B	39.58	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.3792 of 5 stars	$227.06 +3.3%	$366.90 +61.6%	-51.2%	$30.33B	$3.71B	42.13	2,770	Analyst Upgrade Insider Trade
ROIV Roivant Sciences	3.2367 of 5 stars	$35.69 -0.3%	$45.64 +27.9%	+115.6%	$25.92B	$8.26M	N/A	721	Insider Trade
BNTX BioNTech	4.0855 of 5 stars	$97.62 0.0%	$126.00 +29.1%	-10.2%	$24.71B	$2.65B	N/A	7,807	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, ROIV, BNTX, and INSM

How does Kymera Therapeutics compare to Biogen?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Summary

How does Kymera Therapeutics compare to BioNTech?

Summary

How does Kymera Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, ROIV, BNTX, and INSM

How does Kymera Therapeutics compare to Biogen?

Do analysts rate KYMR or BIIB?

Which has preferable earnings & valuation, KYMR or BIIB?

Is KYMR or BIIB more profitable?

Which has more risk and volatility, KYMR or BIIB?

Do insiders & institutionals hold more shares of KYMR or BIIB?

Does the media prefer KYMR or BIIB?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Does the media refer more to ALNY or KYMR?

Which has preferable earnings and valuation, ALNY or KYMR?

Do analysts prefer ALNY or KYMR?

Which has more risk and volatility, ALNY or KYMR?

Do insiders and institutionals hold more shares of ALNY or KYMR?

Is ALNY or KYMR more profitable?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Which has more volatility and risk, KYMR or ROIV?

Do analysts prefer KYMR or ROIV?

Do insiders & institutionals have more ownership in KYMR or ROIV?

Is KYMR or ROIV more profitable?

Does the media favor KYMR or ROIV?

Which has higher valuation and earnings, KYMR or ROIV?

Summary

How does Kymera Therapeutics compare to BioNTech?

Do analysts prefer BNTX or KYMR?

Does the media favor BNTX or KYMR?

Which has more risk & volatility, BNTX or KYMR?

Which has preferable valuation & earnings, BNTX or KYMR?

Is BNTX or KYMR more profitable?

Do institutionals and insiders hold more shares of BNTX or KYMR?

Summary

How does Kymera Therapeutics compare to Insmed?

Which has more risk and volatility, INSM or KYMR?

Do analysts prefer INSM or KYMR?

Is INSM or KYMR more profitable?

Which has higher valuation & earnings, INSM or KYMR?

Does the media prefer INSM or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools